Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients.
Minutolo, Roberto; Zamboli, Pasquale; Chiodini, Paolo; Mascia, Sara; Vitiello, Santo; Stanzione, Giovanna; Bertino, Valerio; Conte, Giuseppe; De Nicola, Luca.
; 30(3): 186-94, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20924174
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage.
Darbepoetin for the anaemia of chronic kidney disease.
Wachstumsfaktoren - Erythropoetine.
Dosing regimen and tolerability of methoxy polyethylene glycol-epoetin beta in Chinese dialysis patients.
Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients.
Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).